Source link : https://www.newshealth.biz/health-news/adalimumab-biosimilars-comparable-with-originator/
TOPLINE: Biosimilars demonstrate comparable drug survival and safety with adalimumab among new users, but patients switching from Humira (the originator product) to biosimilars had a 35% higher discontinuation rate than those who remained on Humira. METHODOLOGY: Researchers conducted a cohort study using data on patients with psoriasis who were treated with adalimumab, a tumor necrosis […]
Author : News Health
Publish date : 2024-11-28 06:45:18
Copyright for syndicated content belongs to the linked Source.